Find the right fit for you - faster
Get tailored insights about working at Hyperion Therapeutics in one quick step.
Hyperion Therapeutics Snapshot
We acquire, develop and efficiently commercialize novel therapeutics to give hope to people suffering from orphan diseases. With a commitment to compassionate care, we focus on creating value for everyone who benefits from our work.
Hyperion Therapeutics, Inc. is a commercial-stage biopharmaceutical company
committed to developing and delivering life-changing treatments for orphan diseases.
The company's first commercial product, RAVICTI (glycerol phenylbutyrate) Oral Liquid,
was approved in February 2013 and is currently being marketed in the United States.
The company also owns worldwide rights to BUPHENYL (sodium phenylbutyrate)
Tablets and Powder, which it markets in the U.S. The compound is also marketed
internationally through business partners. In addition, the company is developing
glycerol phenylbutyrate for the potential treatment of hepatic encephalopathy.
committed to developing and delivering life-changing treatments for orphan diseases.
The company's first commercial product, RAVICTI (glycerol phenylbutyrate) Oral Liquid,
was approved in February 2013 and is currently being marketed in the United States.
The company also owns worldwide rights to BUPHENYL (sodium phenylbutyrate)
Tablets and Powder, which it markets in the U.S. The compound is also marketed
internationally through business partners. In addition, the company is developing
glycerol phenylbutyrate for the potential treatment of hepatic encephalopathy.
